Advertisement
Advertisement
U.S. markets close in 2 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
153.39-0.33 (-0.21%)
As of 01:54PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close153.72
Open152.32
Bid152.98 x 800
Ask152.92 x 900
Day's Range152.32 - 155.51
52 Week Range117.64 - 169.98
Volume446,805
Avg. Volume512,880
Market Cap9.615B
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-7.37
Earnings DateAug 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est201.82
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Jazz Pharmaceuticals plc
    Analyst Report: Jazz Pharmaceuticals plcJazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
    Rating
    Fair Value
    Economic Moat
    26 days agoMorningstar
View more
Advertisement
Advertisement